Genfit S.A. (NASDAQ:GNFT - Get Free Report) was the recipient of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 51,300 shares, a decrease of 23.0% from the April 30th total of 66,600 shares. Currently, 0.1% of the company's stock are short sold. Based on an average daily trading volume, of 13,200 shares, the short-interest ratio is currently 3.9 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and issued a $13.00 price target on shares of Genfit in a research note on Friday, February 7th.
View Our Latest Stock Analysis on Genfit
Genfit Price Performance
GNFT stock traded down $0.31 during mid-day trading on Friday, reaching $4.16. The company had a trading volume of 2,761 shares, compared to its average volume of 12,817. Genfit has a fifty-two week low of $2.55 and a fifty-two week high of $6.42. The firm has a fifty day simple moving average of $3.90 and a 200 day simple moving average of $3.81. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74.
Institutional Investors Weigh In On Genfit
A hedge fund recently bought a new stake in Genfit stock. Millennium Management LLC bought a new stake in Genfit S.A. (NASDAQ:GNFT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit at the end of the most recent reporting period. 2.24% of the stock is currently owned by hedge funds and other institutional investors.
About Genfit
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
Before you consider GENFIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GENFIT wasn't on the list.
While GENFIT currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
